Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Therapeutic efficacy of mesenchymal stromal cells and secretome in pulmonary arterial hypertension: A systematic review and meta-analysis.
Biochimie ( IF 3.3 ) Pub Date : 2019-10-31 , DOI: 10.1016/j.biochi.2019.10.016 Suleiman Alhaji Muhammad 1 , Abdullahi Yahaya Abbas 1 , Yusuf Saidu 1 , Sharida Fakurazi 2 , Lawal Suleiman Bilbis 1
Biochimie ( IF 3.3 ) Pub Date : 2019-10-31 , DOI: 10.1016/j.biochi.2019.10.016 Suleiman Alhaji Muhammad 1 , Abdullahi Yahaya Abbas 1 , Yusuf Saidu 1 , Sharida Fakurazi 2 , Lawal Suleiman Bilbis 1
Affiliation
|
Mesenchymal stromal cells (MSCs) and secretome are promising therapies for pulmonary arterial hypertension (PAH). This meta-analysis aimed to provide a precise estimate and compare the therapeutic efficacy of MSC and secretome in PAH. We searched six databases (CINAHL, Cochrane, Ovid Medline, PubMed, Science Direct and Scopus) until December 2018 using search terms related to MSCs, secretome and PAH. Twenty-three studies were included for the meta-analysis. The effect size of pulmonary hemodynamics and right ventricular hypertrophy markers was estimated using random effects model. MSCs and secretome significantly improved pulmonary hemodynamics and right ventricular hypertrophy compared to control. Comparison between MSCs and secretome indicate no significant difference in reducing right ventricular systolic pressure (RVSP) and medial wall thickening (MWT). However, treatment of PAH with secretome significantly improved mean pulmonary arterial pressure (mPAP) (p = 0.018) and right ventricular/left ventricular + septum (RV/LV+S) (p = 0.017) better than MSCs. Meta-regression shows that cell type (p = 0.034) is a predictor of MSCs to reduce RVSP in PAH. Similarly, the effect of secretome on MWT was significantly (p = 0.011) better at 4 weeks compared to 2 weeks of intervention. The overall risk of bias ranges from low to moderate; however, some of the essential elements required in reports of animal trials were not reported. There was evidence of publication bias for RV/LV+S and MWT, but not RVSP. This meta-analysis provides evidence of the therapeutic benefits of MSCs and secretome in PAH and the effect of secretome was similar or superior to MSCs.
中文翻译：
间充质基质细胞和分泌组在肺动脉高压中的治疗功效：系统评价和荟萃分析。
间充质基质细胞（MSCs）和分泌组是治疗肺动脉高压（PAH）的有前途的疗法。这项荟萃分析旨在提供准确的估计并比较MSC和促分泌素在PAH中的治疗效果。我们搜索了六个数据库（CINAHL，Cochrane，Ovid Medline，PubMed，Science Direct和Scopus），直到2018年12月为止，使用的搜索词与MSCs，secretome和PAH有关。荟萃分析包括23项研究。使用随机效应模型估算肺血流动力学和右心室肥大标志物的效应大小。与对照组相比，MSC和分泌组显着改善了肺血流动力学和右心室肥大。MSC和分泌组之间的比较表明，在降低右心室收缩压（RVSP）和内侧壁增厚（MWT）方面无显着差异。但是，用分泌组治疗PAH的平均肺动脉压（mPAP）（p = 0.018）和右心室/左心室+隔垫（RV / LV + S）（p = 0.017）显着优于MSC。元回归表明，细胞类型（p = 0.034）是MSC减少PAH中RVSP的预测因子。同样，与2周的干预相比，第4周时，分泌组对MWT的影响显着更好（p = 0.011）。总体偏见风险从低到中等。但是，没有报告动物试验报告中要求的某些基本要素。有证据表明RV / LV + S和MWT出现了出版偏倚，但RVSP没有。
更新日期：2019-11-01
中文翻译：
间充质基质细胞和分泌组在肺动脉高压中的治疗功效：系统评价和荟萃分析。
间充质基质细胞（MSCs）和分泌组是治疗肺动脉高压（PAH）的有前途的疗法。这项荟萃分析旨在提供准确的估计并比较MSC和促分泌素在PAH中的治疗效果。我们搜索了六个数据库（CINAHL，Cochrane，Ovid Medline，PubMed，Science Direct和Scopus），直到2018年12月为止，使用的搜索词与MSCs，secretome和PAH有关。荟萃分析包括23项研究。使用随机效应模型估算肺血流动力学和右心室肥大标志物的效应大小。与对照组相比，MSC和分泌组显着改善了肺血流动力学和右心室肥大。MSC和分泌组之间的比较表明，在降低右心室收缩压（RVSP）和内侧壁增厚（MWT）方面无显着差异。但是，用分泌组治疗PAH的平均肺动脉压（mPAP）（p = 0.018）和右心室/左心室+隔垫（RV / LV + S）（p = 0.017）显着优于MSC。元回归表明，细胞类型（p = 0.034）是MSC减少PAH中RVSP的预测因子。同样，与2周的干预相比，第4周时，分泌组对MWT的影响显着更好（p = 0.011）。总体偏见风险从低到中等。但是，没有报告动物试验报告中要求的某些基本要素。有证据表明RV / LV + S和MWT出现了出版偏倚，但RVSP没有。
京公网安备 11010802027423号